On May 1, 2023 at 09:34:16 ET an unusually large $544.00K block of Call contracts in TG Therapeutics (TGTX) was sold, with a strike price of $18.00 / share, expiring in 109 day(s) (on August 18, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 3.15 sigmas above the mean, placing it in the 99.99th percentile of all recent large trades made in TGTX options.

This trade was first picked up on Fintel’s real time Options Flow tool, where unusual option trades are highlighted.

What is the Fund Sentiment?

There are 379 funds or institutions reporting positions in TG Therapeutics. This is an increase of 30 owner(s) or 8.60% in the last quarter. Average portfolio weight of all funds dedicated to TGTX is 0.18%, an increase of 293.90%. Total shares owned by institutions decreased in the last three months by 5.22% to 98,597K shares. The put/call ratio of TGTX is 0.26, indicating a bullish outlook.

Analyst Price Forecast Suggests 15.27% Downside

As of April 24, 2023, the average one-year price target for TG Therapeutics is $21.04. The forecasts range from a low of $6.06 to a high of $29.40. The average price target represents a decrease of 15.27% from its latest reported closing price of $24.83.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for TG Therapeutics is $72MM, an increase of 2,503.23%. The projected annual non-GAAP EPS is -$1.17.

What are Other Shareholders Doing?

Ergoteles holds 126K shares representing 0.08% ownership of the company. In it’s prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.

LPL Financial holds 39K shares representing 0.03% ownership of the company. In it’s prior filing, the firm reported owning 27K shares, representing an increase of 29.55%. The firm increased its portfolio allocation in TGTX by 151.82% over the last quarter.

Public Employees Retirement Association Of Colorado holds 17K shares representing 0.01% ownership of the company. No change in the last quarter.

Allspring Global Investments Holdings holds 80K shares representing 0.05% ownership of the company. In it’s prior filing, the firm reported owning 6K shares, representing an increase of 91.90%. The firm increased its portfolio allocation in TGTX by 1,422.74% over the last quarter.

TLSTX – Stock Index Fund holds 3K shares representing 0.00% ownership of the company. In it’s prior filing, the firm reported owning 2K shares, representing an increase of 13.04%. The firm increased its portfolio allocation in TGTX by 116.74% over the last quarter.

TG Therapeutics Background Information
(This description is provided by the company.)

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQTM (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.

See all TG Therapeutics regulatory filings.

This article originally appeared on Fintel

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.